{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:18:42Z","timestamp":1793726322204,"version":"4.6.1"},"reference-count":52,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1111\/jcpt.12363","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T09:38:55Z","timestamp":1458380335000},"page":"119-127","source":"Crossref","is-referenced-by-count":13,"title":["Neprilysin inhibition with sacubitril\/valsartan in the treatment of heart failure: mortality bang for your buck"],"prefix":"10.1155","volume":"41","author":[{"given":"A. J.","family":"Ansara","sequence":"first","affiliation":[{"name":"Department of Pharmacy; Indiana University Health Methodist Hospital; Indianapolis IN USA"},{"name":"Department of Pharmacy Practice; Butler University College of Pharmacy and Health Sciences; Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Kolanczyk","sequence":"additional","affiliation":[{"name":"Department of Pharmacy; Loyola University Medical Center; Maywood IL USA"},{"name":"Department of Pharmacy Practice; Midwestern University Chicago College of Pharmacy; Downers Grove IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Koehler","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice; Butler University College of Pharmacy and Health Sciences; Indianapolis IN USA"},{"name":"Pulmonary Rehabilitation and Transitional Care; Indiana University Health; Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2016,3,18]]},"reference":[{"key":"10.1111\/jcpt.12363-BIB0001|jcpt12363-cit-0001","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12363-BIB0002|jcpt12363-cit-0002","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1111\/jcpt.12363-BIB0003|jcpt12363-cit-0003","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jama.292.3.344","article-title":"Trends in heart failure incidence and survival in a community-based population","volume":"292","author":"Roger","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12363-BIB0004|jcpt12363-cit-0004","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa020265","article-title":"Long-term trends in the incidence of and survival with heart failure","volume":"347","author":"Levy","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12363-BIB0005|jcpt12363-cit-0005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCOUTCOMES.109.883256","article-title":"Patterns of hospital performance in acute myocardial infarction and 10 heart failure 30-day mortality and readmission","volume":"2","author":"Krumholz","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1111\/jcpt.12363-BIB0006|jcpt12363-cit-0006","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1161\/CIR.0b013e31828124ad","article-title":"Heart disease and stroke statistics-2013 update: a report from the 49 American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12363-BIB0007|jcpt12363-cit-0007","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa012175","article-title":"Long-term mechanical left ventricular assistance for end-stage heart failure","volume":"345","author":"Rose","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12363-BIB0008|jcpt12363-cit-0008","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1056\/NEJMoa053063","article-title":"Left ventricular assist device and drug therapy for the reversal of heart failure","volume":"355","author":"Birks","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12363-BIB0009|jcpt12363-cit-0009","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12363-BIB0010|jcpt12363-cit-0010","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","article-title":"Natriuretic peptides","volume":"50","author":"Daniels","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12363-BIB0011|jcpt12363-cit-0011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1210\/er.2005-0014","article-title":"Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions","volume":"27","author":"Potter","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1111\/jcpt.12363-BIB0012|jcpt12363-cit-0012","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0002-8703(98)70054-7","article-title":"Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease","volume":"135","author":"Stein","year":"1998","journal-title":"Am Heart J"},{"key":"10.1111\/jcpt.12363-BIB0013|jcpt12363-cit-0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1592\/phco.22.1.27.33502","article-title":"A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and heart failure","volume":"22","author":"Nathisuwan","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1111\/jcpt.12363-BIB0014|jcpt12363-cit-0014","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jacc.2004.10.067","article-title":"C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction","volume":"45","author":"Soeki","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12363-BIB0015|jcpt12363-cit-0015","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1111\/jcpt.12363-BIB0016|jcpt12363-cit-0016","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12363-BIB0017|jcpt12363-cit-0017","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.pharmthera.2009.02.009","article-title":"Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics","volume":"122","author":"Tsai","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1111\/jcpt.12363-BIB0018|jcpt12363-cit-0018","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","article-title":"Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension","volume":"116","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12363-BIB0019|jcpt12363-cit-0019","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/eurjhf\/hfr147","article-title":"Phosphodiesterase-5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study","volume":"14","author":"Guazzi","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1111\/jcpt.12363-BIB0020|jcpt12363-cit-0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCHEARTFAILURE.110.944694","article-title":"PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebocontrolled study","volume":"4","author":"Guazzi","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1111\/jcpt.12363-BIB0021|jcpt12363-cit-0021","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12363-BIB0022|jcpt12363-cit-0022","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12363-BIB0023|jcpt12363-cit-0023","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12363-BIB0024|jcpt12363-cit-0024","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12363-BIB0025|jcpt12363-cit-0025","first-page":"1531","article-title":"Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized clinical trial","volume":"287","author":"Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF)","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12363-BIB0026|jcpt12363-cit-0026","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12363-BIB0027|jcpt12363-cit-0027","first-page":"F863","article-title":"Effects of synthetic atrial natriuretic factor on renal function and renin release","volume":"247","author":"Burnett","year":"1984","journal-title":"Am J Physiol"},{"key":"10.1111\/jcpt.12363-BIB0028|jcpt12363-cit-0028","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1172\/JCI112172","article-title":"Effect of atrial peptides on aldosterone production","volume":"76","author":"Atarashi","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1111\/jcpt.12363-BIB0029|jcpt12363-cit-0029","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1440-1681.1995.tb01919.x","article-title":"Role of atrial natriuretic peptide in long-term volume homeostasis","volume":"22","author":"Lohmeier","year":"1995","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1111\/jcpt.12363-BIB0030|jcpt12363-cit-0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00004872-199207000-00002","article-title":"Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension","volume":"10","author":"Bevan","year":"1992","journal-title":"J Hypertens"},{"key":"10.1111\/jcpt.12363-BIB0031|jcpt12363-cit-0031","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/01.HYP.26.6.1160","article-title":"Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin","volume":"26","author":"Ando","year":"1995","journal-title":"Hypertension"},{"key":"10.1111\/jcpt.12363-BIB0032|jcpt12363-cit-0032","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/13543784.8.1.79","article-title":"The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in men","volume":"8","author":"McDowell","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/jcpt.12363-BIB0033|jcpt12363-cit-0033","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(05)77712-6","article-title":"Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure","volume":"351","author":"Cleland","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12363-BIB0034|jcpt12363-cit-0034","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cardfail.2010.04.005","article-title":"Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline","volume":"16","author":"Lindenfeld","year":"2010","journal-title":"J Card Fail"},{"key":"10.1111\/jcpt.12363-BIB0035|jcpt12363-cit-0035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure. IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12363-BIB0036|jcpt12363-cit-0036","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"The Digitalis Investigation Group","year":"1997","journal-title":"N Engl J Med"},{"issue":"Suppl. A","key":"10.1111\/jcpt.12363-BIB0037|jcpt12363-cit-0037","first-page":"185A","article-title":"Long-term beneficial hemodynamic and neurohormonal effects of vasopeptidase inhibition with omapatrilat in heart failure","volume":"32","author":"Ikram","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12363-BIB0038|jcpt12363-cit-0038","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12363-BIB0039|jcpt12363-cit-0039","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacc.2012.03.023","article-title":"Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial","volume":"60","author":"Fiuzat","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12363-BIB0040|jcpt12363-cit-0040","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1161\/CIRCULATIONAHA.109.192065","article-title":"2009 Focused update incorporated into the ACC\/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"119","author":"Jessup","year":"2009","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12363-BIB0041|jcpt12363-cit-0041","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12363-BIB0042|jcpt12363-cit-0042","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12363-BIB0043|jcpt12363-cit-0043","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1111\/jcpt.12363-BIB0044|jcpt12363-cit-0044","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1161\/hy1201.096569","article-title":"Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients","volume":"38","author":"Campese","year":"2001","journal-title":"Hypertension"},{"key":"10.1111\/jcpt.12363-BIB0045|jcpt12363-cit-0045","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12363-BIB0046|jcpt12363-cit-0046","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2013","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12363-BIB0047|jcpt12363-cit-0047","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12237","article-title":"Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension","volume":"16","author":"Weber","year":"2013","journal-title":"J Clin Hypertens"},{"key":"10.1111\/jcpt.12363-BIB0048|jcpt12363-cit-0048","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12363-BIB0049|jcpt12363-cit-0049","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12363-BIB0050|jcpt12363-cit-0050","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomized controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12363-BIB0051|jcpt12363-cit-0051","unstructured":"Novartis Pharmaceuticals PARAGON-HF 2000 http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01920711"},{"key":"10.1111\/jcpt.12363-BIB0052|jcpt12363-cit-0052","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cjca.2014.10.022","article-title":"The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications","volume":"15","author":"Moe","year":"2015","journal-title":"Can J Cardiol"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12363","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12363\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:06:16Z","timestamp":1671818776000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,18]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12363","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,18]]}}}